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More than 85% of newborns develop some 
degree of jaundice during the first days of life. 
Often a benign condition, the yellowish disc-
olouration of the skin, sclerae, and mucous 
membranes in newborn infants is caused by 
unconjugated hyperbilirubinaemia, which 
may result from increased production of bili-
rubin, limited ability to conjugate bilirubin, 
and/or slow hepatic-enteric clearance of 
bilirubin.1 A small proportion of newborns 
develops extreme hyperbilirubinaemia, 
that is, a total serum bilirubin (TSB) level of 
25 mg/dL (428 µmol/L) or more. When it 
is not timely recognised or treated, extreme 
unconjugated hyperbilirubinaemia may lead 
to acute bilirubin encephalopathy. This in 
turn carries a risk of developing a spectrum 
of long-term neurological sequelae known 
as kernicterus spectrum disorders (KSD), 
encompassing ‘classical kernicterus’ but also 
milder forms of permanent brain damage 
caused by bilirubin neurotoxicity.1 2 World-
wide, it is estimated that extreme hyperbiliru-
binaemia affects at least 481 000 late-preterm 
and term newborn infants annually, resulting 
in 114 000 deaths and more than 63 000 
survivors with moderate or severe long-term 
disability.1 3 More than 75% of affected infants 
live in low-income and lower-middle-income 
countries. Moreover, in South Asia severe 
hyperbilirubinaemia is the seventh leading 
cause of neonatal mortality.1 
When timely recognised, clinically signifi-
cant hyperbilirubinaemia can be treated with 
conventional phototherapy and in more severe 
cases exchange transfusion, thus reducing 
the risk of KSD. Relatively uncommon in 
high-income countries, exchange transfu-
sions are performed regularly in low-income 
and lower-middle-income countries.3 In these 
countries early recognition of hyperbiliru-
binaemia can be difficult. In low-resource 
settings home births are common, and for 
institutional deliveries early post-discharge 
follow-up controls are not always feasible. In 
addition, parental unawareness and logistical 
challenges may result in poor care-seeking 
behaviour. In these settings infants often 
present with extreme hyperbilirubinemia and 
moderate to severe stages of acute bilirubin 
encephalopathy, resulting in high mortality 
and morbidity rates.1 3 Traditionally, neonatal 
jaundice is determined by visual inspection. 
If clinically relevant jaundice is suspected, 
TSB is quantified in blood to assess the need 
for treatment. However, visual inspection 
of neonatal jaundice correlates poorly with 
the TSB level, particularly in non-Caucasian 
infants.1 Moreover, in areas with limited 
resources laboratory testing can be chal-
lenging due to the high cost and lack of 
trained technical personnel. Transcutaneous 
bilirubin (TcB) devices have been developed 
as potential non-invasive alternatives to visual 
inspection. Several observational studies have 
shown a good correlation between TSB and 
TcB measurements. TcB can be performed by 
nurses or trained health workers with limited 
education. Coordinated TcB screening in a 
Canadian community setting was associated 
with a 55% reduction in severe hyperbiliru-
binaemia compared with visual inspection 
alone.4
Shah et al have evaluated a care improve-
ment initiative in a large hospital in Karachi, 
the largest city in Pakistan.5 TcB screening of 
visibly jaundiced, otherwise well babies was 
implemented and clinical characteristics and 
jaundice-related outcomes were compared 
in the 6 months before vs 6 months after 
implementation. There was a 79% reduction 
in the number of blood samples taken for 
TSB quantification following TcB implemen-
tation; at the same time the proportion of 
infants receiving phototherapy increased (6% 
after vs 4% before implementation of TcB). 
Overall this is a useful uncontrolled before-
after study, and the first to investigate the 
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effectiveness of using a TcB device to diagnose neonatal 
jaundice in a Pakistani population. The considerable 
reduction in TSB sampling following TcB implementa-
tion as compared with other studies (in general reduc-
tion of 40% to 50%), was attributed to excessive sampling 
due to the high incidence of severe hyperbilirubinaemia 
in South Asia. The increased use of phototherapy in the 
post-implementation period suggests improved recogni-
tion of hyperbilirubinaemia, although it is possible that 
this includes some over-treatment. In this study the vast 
majority of infants were indeed screened, suggesting a 
low threshold for selection for screening. It is however 
important to note that selective screening based on visible 
jaundice still carries a risk of under-diagnosis. Universal 
TcB screening may be a valuable approach to avoid this 
risk and is currently under investigation in the primary 
care setting (Netherlands Trial Register: NTR7187).
In the Pakistani study it would have been informative 
to have other indicators evaluated as well to determine 
added value and/or safety aspects, such as changes in 
exchange transfusions, duration of phototherapy, or 
duration of hospital admission. The mean TSB peak 
was relatively low in this study population, 9.2 mg/dL 
before and 10.2 mg/dL after TcB implementation.5 
Most likely these low-risk infants are not representative 
of the large proportion of infants with severe hyperbil-
irubinemia admitted to non-private, non-tertiary care 
hospitals in Pakistan. Some other limitations of this study 
were the small sample size, short duration of the study 
(12 months) and the single centre design. Whether TcB 
devices can impact the high incidence of severe hyper-
bilirubinemia at the population level in low-income and 
lower-middle-income countries like Pakistan is doubtful. 
That is, the majority of patients with extreme hyperbiliru-
binaemia and moderate to severe stages of acute bilirubin 
encephalopathy present from home. As such, early recog-
nition of clinically relevant hyperbilirubinaemia is partic-
ularly needed in primary care/community based settings. 
Whereas the current study indicates that TcB screening 
may be useful in a large institution, the price of TcB 
devices and logistical challenges are obvious barriers to 
implementation in primary healthcare settings in low-in-
come and lower-middle-income countries. Low-cost and 
minimally invasive tools for hyperbilirubinaemia recogni-
tion including smartphone technology and point-of-care 
TSB quantification have emerged and may hold promise 
for early detection of hyperbilirubinaemia in poor-re-
source settings.1 Proper education of communities 
and healthcare providers remains essential to increase 
awareness of the main risk factors for severe hyperbiliru-
binaemia, and facilitate early recognition, timely referral 
for evaluation and treatment, and adequate follow-up.
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